These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 33676886)

  • 41. Importance of balancing follow-up time and impact of oral-anticoagulant users' selection when evaluating medication adherence in atrial fibrillation patients treated with rivaroxaban and apixaban.
    Coleman C; Yuan Z; Schein J; Crivera C; Ashton V; Laliberté F; Lefebvre P; Peterson ED
    Curr Med Res Opin; 2017 Jun; 33(6):1033-1043. PubMed ID: 28366075
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data.
    Kushnir M; Choi Y; Eisenberg R; Rao D; Tolu S; Gao J; Mowrey W; Billett HH
    Lancet Haematol; 2019 Jul; 6(7):e359-e365. PubMed ID: 31133411
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A prediction model for nonpersistence or nonadherence to direct oral anticoagulants in hospitalized patients with atrial fibrillation.
    Wirbka L; Ruff C; Haefeli WE; Meid AD
    J Manag Care Spec Pharm; 2022 Oct; 28(10):1161-1172. PubMed ID: 36125062
    [No Abstract]   [Full Text] [Related]  

  • 44. The role of rivaroxaban in atrial fibrillation and acute coronary syndromes.
    Reddy P; Giugliano RP
    J Cardiovasc Pharmacol Ther; 2014 Nov; 19(6):526-32. PubMed ID: 24659084
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Rivaroxaban Versus Warfarin for Stroke Prevention and Venous Thromboembolism Treatment in Extreme Obesity and High Body Weight.
    Perales IJ; San Agustin K; DeAngelo J; Campbell AM
    Ann Pharmacother; 2020 Apr; 54(4):344-350. PubMed ID: 31672028
    [No Abstract]   [Full Text] [Related]  

  • 46. Comparison of Adherence to Rivaroxaban Versus Apixaban Among Patients With Atrial Fibrillation.
    McHorney CA; Peterson ED; Laliberté F; Germain G; Nelson WW; Crivera C; Schein J; Lefebvre P
    Clin Ther; 2016 Nov; 38(11):2477-2488. PubMed ID: 27789043
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: A retrospective analysis of the rivaroxaban once daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF)].
    Divisón Garrote JA; Escobar Cervantes C
    Semergen; 2016; 42(4):260-2. PubMed ID: 26653339
    [No Abstract]   [Full Text] [Related]  

  • 48. Comparative safety and effectiveness of dabigatran vs. rivaroxaban and apixaban in patients with non-valvular atrial fibrillation: a retrospective study from a large healthcare system.
    Villines TC; Ahmad A; Petrini M; Tang W; Evans A; Rush T; Thompson D; Oh K; Schwartzman E
    Eur Heart J Cardiovasc Pharmacother; 2019 Apr; 5(2):80-90. PubMed ID: 30500885
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Non-Vitamin K Antagonist Oral Anticoagulant Dosing in Patients With Atrial Fibrillation and Renal Dysfunction.
    Yao X; Shah ND; Sangaralingham LR; Gersh BJ; Noseworthy PA
    J Am Coll Cardiol; 2017 Jun; 69(23):2779-2790. PubMed ID: 28595692
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effectiveness and Safety of Standard-Dose Nonvitamin K Antagonist Oral Anticoagulants and Warfarin Among Patients With Atrial Fibrillation With a Single Stroke Risk Factor: A Nationwide Cohort Study.
    Lip GYH; Skjøth F; Nielsen PB; Kjældgaard JN; Larsen TB
    JAMA Cardiol; 2017 Aug; 2(8):872-881. PubMed ID: 28614582
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [New Oral Anticoagulants During Catheter Ablation of Atrial Fibrillation. Experience With Rivaroxaban].
    Kazakov AI; Yashin SM; Lyan EV; Ayrapetyan AV
    Kardiologiia; 2015; 55(8):30-4. PubMed ID: 26761969
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Oral anticoagulation in atrial fibrillation: What is the guideline for using new drugs?].
    Ibáñez Pérez de Viñaspre JA; Gómez Bitrian J; Royo Hernández R; de Azúa Jiménez M; Marco López C; Urieta González L
    Semergen; 2018; 44(5):297-303. PubMed ID: 28867369
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Transesophageal vs. intracardiac echocardiographic screening in patients undergoing atrial fibrillation ablation with uninterrupted rivaroxaban.
    Tsyganov A; Shapieva A; Sandrikov V; Fedulova S; Mironovich S; Dzeranova A; Lyan E
    BMC Cardiovasc Disord; 2017 Jun; 17(1):171. PubMed ID: 28662693
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Noncentral Nervous System Systemic Embolism in Patients With Atrial Fibrillation: Results From ROCKET AF (Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).
    Orgel R; Wojdyla D; Huberman D; Halperin JL; Breithardt G; Singer DE; Fox KAA; Hankey GJ; Mahaffey KW; Jones WS; Patel MR
    Circ Cardiovasc Qual Outcomes; 2017 May; 10(5):. PubMed ID: 28495674
    [No Abstract]   [Full Text] [Related]  

  • 55. Design and Rationale of the RELAXED (Recurrent Embolism Lessened by rivaroxaban, an Anti-Xa agent, of Early Dosing for acute ischemic stroke and transient ischemic attack with atrial fibrillation) Study.
    Yasaka M; Minematsu K; Toyoda K; Yamagami H; Yoshimura S; Nagao T; Mori E; Hirano T; Hamasaki T; Yamaguchi T
    J Stroke Cerebrovasc Dis; 2016 Jun; 25(6):1342-8. PubMed ID: 26987488
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Thrombocytopenia.
    Janion-Sadowska A; Papuga-Szela E; Łukaszuk R; Chrapek M; Undas A
    J Cardiovasc Pharmacol; 2018 Sep; 72(3):153-160. PubMed ID: 29985282
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Patient adherence to rivaroxaban in deep vein thrombosis, a cohort study in Switzerland: quantitative results.
    Dotta-Celio J; Alatri A; Locatelli I; Salvi M; Bugnon O; Schneider MP; Mazzolai L
    Int J Clin Pharm; 2019 Dec; 41(6):1625-1633. PubMed ID: 31776778
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Direct comparative effectiveness and safety between non-vitamin K antagonist oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies.
    Li G; Lip GYH; Holbrook A; Chang Y; Larsen TB; Sun X; Tang J; Mbuagbaw L; Witt DM; Crowther M; Thabane L; Levine MAH
    Eur J Epidemiol; 2019 Feb; 34(2):173-190. PubMed ID: 29948370
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Contemporary Trends in Oral Anticoagulant Prescription in Atrial Fibrillation Patients at Low to Moderate Risk of Stroke After Guideline-Recommended Change in Use of the CHADS
    Katz DF; Maddox TM; Turakhia M; Gehi A; O'Brien EC; Lubitz SA; Turchin A; Doros G; Lei L; Varosy P; Marzec L; Hsu JC
    Circ Cardiovasc Qual Outcomes; 2017 May; 10(5):. PubMed ID: 28506981
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparative effectiveness, safety, and costs of rivaroxaban and warfarin among morbidly obese patients with atrial fibrillation.
    Peterson ED; Ashton V; Chen YW; Wu B; Spyropoulos AC
    Am Heart J; 2019 Jun; 212():113-119. PubMed ID: 30981035
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.